The Personal Patient Profile Decision Support for Patients With Bladder Cancer
NCT05033067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2026-04-24
Summary
There is a pressing need to develop a personalized, value-based decisional tool for bladder cancer patients undergoing radical cystectomy (bladder removal) and urinary diversion to help them with communication with the physicians, shared decision making, and preparation for disease-management and follow-up care. The proposed intervention, the Personal Patient Profile - Bladder Cancer (P3-BC), will be the first intervention to address these issues. Results of this pilot randomized feasibility study will provide evidence of the feasibility and acceptability of the P3-BC and will guide further refinement of the tool for a larger experimental trial, with potential dissemination of the program via the Internet and hand-held computing devices.
Conditions
Interventions
- BEHAVIORAL
-
P3BC
The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
Sponsors & Collaborators
- collaborator OTHER
-
National Institute of Nursing Research (NINR)
collaborator NIH -
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Nihal Mohamed, PhD · Icahn School of Medicine at Mount Sinai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-10
- Primary Completion
- 2024-08-31
- Completion
- 2024-08-31
Countries
- United States
Study Locations
More Related Trials
-
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561 ·Status: RECRUITING
-
Health-Related Quality of Life in Patients With Bladder Cancer
NCT00744744 ·Status: COMPLETED
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127 ·Status: RECRUITING
-
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
NCT05739968 ·Status: RECRUITING ·Phase: NA
-
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT06350734 ·Status: ACTIVE_NOT_RECRUITING
-
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
NCT00003930 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
NCT05236218 ·Status: UNKNOWN
-
Multidisciplinary Bladder-preservation Therapy for Bladder Cancer
NCT03756207 ·Status: UNKNOWN ·Phase: NA
-
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
NCT02716961 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
NCT02365766 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quality of Life and Symptom Management in Patients With Bladder Cancer
NCT00772018 ·Status: COMPLETED
-
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036 ·Status: COMPLETED
-
Personalized Urine Biomarker for Patients With Bladder Cancer
NCT05467267 ·Status: UNKNOWN
-
Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer
NCT02688348 ·Status: WITHDRAWN ·Phase: NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
NCT07048496 ·Status: RECRUITING ·Phase: NA
-
Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy
NCT02039310 ·Status: COMPLETED
-
Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors
NCT03863028 ·Status: COMPLETED
-
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
NCT00055601 ·Status: COMPLETED ·Phase: PHASE2
-
Bladder Cancer Patient-Reported Outcomes
NCT01090388 ·Status: COMPLETED
-
Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy
NCT03307200 ·Status: COMPLETED
-
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
NCT06412874 ·Status: COMPLETED
-
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NCT05123625 ·Status: RECRUITING ·Phase: NA
-
A Diagnostic for the Early Detection of Bladder Cancer
NCT05347342 ·Status: ACTIVE_NOT_RECRUITING
-
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
NCT00776178 ·Status: COMPLETED
-
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
NCT02145390 ·Status: TERMINATED ·Phase: NA